title: Effect of the Honan intraocular pressure reducer on intraocular pressure increase following intravitreal injection using the tunneled scleral technique.
abstract: OBJECTIVE
  To determine the effect of the Honan intraocular pressure reducer (HIPR) on the rise in intraocular pressure (IOP) after an intravitreal injection using a tunneled scleral incision.
  
  
  METHODS
  This was a prospective, comparative, controlled, non-randomized clinical study.
  
  
  METHODS
  Sixty eyes of 60 patients who received intravitreal injections with the tunneled scleral technique were allocated into two groups, one with and one without application of the HIPR. The pre-operative IOP both before and after application of the HIPR, and the IOP immediately postoperative, and at 3 and 10 min postoperatively were evaluated. The vitreous reflux was estimated by measuring the large diameter of the sub-conjunctival bleb formed after intravitreal injection.
  
  
  RESULTS
  The pre-operative IOP in the HIPR group was significantly lower than that in the non-HIPR group following application of the HIPR. The immediate postoperative IOP was significantly lower in the HIPR group than in the non-HIPR group. The IOP at 10 min postoperatively was lower in the HIPR group than in the non-HIPR group. There was no difference in the amount of vitreous reflux between the HIPR and the non-HIPR groups.
  
  
  CONCLUSIONS
  The use of the HIPR reduces the IOP after an intravitreal injection using the tunneled scleral technique. However, the HIPR does not appear to affect a reduction in the vitreous reflux.
authors.affiliation: Department of Ophthalmology and Visual Science, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors.forename: Kyu-Seop
authors.initials: KS
authors.lastname: Kim
authors.forename: Donghyun
authors.initials: D
authors.lastname: Jee
mesh_terms: D000368:Aged; D000772:Anesthesia, Local / Q000379:methods; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D021721:Balloon Occlusion / Q000295:instrumentation*; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D007429:Intraocular Pressure; D058449:Intravitreal Injections / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000209:etiology / Q000517:prevention & control*; D011446:Prospective Studies; D012590:Sclera; D013524:Surgical Flaps; D014065:Tonometry, Ocular; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab